-
Mashup Score: 23
TPS4205 Background: MRD detected by presence of circulating tumor DNA (ctDNA) after intended curative treatment is associated with high risk of relapse in pancreatic cancer. Early treatment of patients with presence of ctDNA after completion of surgery +/- adjuvant therapy may offer an opportunity to clear ctDNA and improve outcomes. TG01 is a RAS-neoantigen peptide vaccine adjuvanted by QS-21 (Stimulon) targeting the seven most frequent codon 12-13 RAS mutations. TG01 has previously demonstrated ability to activate mutant RAS specific CD4+ and CD8+ T-cell responses in vaccinated patients and repeated TG01 dosing in resected pancreatic cancer was found to be well tolerated and associated with a median OS of 33.4 months (95% CI 24.0, 45.8)1,2. Checkpoint inhibitors as single agents have not shown anti-tumor activity in pancreatic cancer, suggesting that a priming agent inducing tumor-specific T-cells may be required to support efficacy. Balstilimab is a human monoclonal antibody targeti
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Potential Therapy Takes a Two-Prong Attack on Pancreatic Cancer - 7 month(s) ago
With a focus on targeting cell metabolism, Dr. Anup Kasi leads a clinical trial of a new agent in combination with gemcitabine.
Source: letswinpc.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Program Guide – ASCO Meeting Program Guide - 12 month(s) ago
AuthorsAnup KasiUniversity of Kansas Cancer Center, Westwood, KSAnup Kasi, Francisco Diaz, Raed Moh’d Taiseer Al-Rajabi, Joaquina Celebre Baranda, Erin Carroll, Cathey Belcher, Mojtaba Olyaee, Amit Rastogi, Timothy Schmitt, Sean Kumer, Atta Nawabi, Harsh B Pathak, Andrew K. Godwin, Mary Markiewicz, Weijing SunOrganizationsUniversity of Kansas Cancer Center, Westwood, KS, University of Kansas…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@Aiims1742 @BenWestphalen @OncoAlert @ASCO @PancPathologist @graokane @MadameSurgeon @EileenMOReilly @KenOliveLab @ArndtVogel @pashtoonkasi @MPishvaian @letswinpc @PanCAN @lustgartenfdn @DrShubhamPant Neat study @Aiims1742 @DrShubhamPant @EileenMOReilly . We have a similar study targeting MRD in resected RAS mutated #pancreatic with vaccine TG01/QS-21 +/-balstilimab: A randomized phase 2 study (TESLA). Presenting at #ASCO23 https://t.co/2Y7Z6110AO
-
-
Mashup Score: 0
Morning Rounds – Roundup of Current NewsDr. Austin Findley, director, minimally invasive gynecologic surgery, The University of Kansas Health SystemAn estima…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Efficacy of Oral Cryotherapy During Oxaliplatin Infusion in Preventing Oral Thermal Hyperalgesia: A Randomized Trial - PubMed - 2 year(s) ago
Oral cryotherapy is a tolerable and cost-effective method of diminishing OTH in patients receiving oxaliplatin chemotherapy, and seems to be most effective in the early stages of treatment.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@MPishvaian @TumorBoardTues @maryam_lustberg @Dr_RShatsky @drteplinsky @JohnEbbenMDPhD @NEJM @gary_lyman @DrTJM_MD @g_mountzios @IdoWolf5 @NicoleKuderer @FlaviaJacobs_ @CarmenCriscit @mauricallari @DrSGraff @dradesnoyers @SoniaPernas @OlofssonBagge @AlisonSvoboda @Icro_Meattini @Mattia_Rediti @kevinpunie @stephaniemwong @naborala @SWOG @scalpcooling Haven’t tried prescribing scalp cooling with Oxaliplatin but oral icing works fairly well https://t.co/uBfr92IhN7
-
-
Mashup Score: 1
This cross-sectional study evaluates anti–SARS-CoV-2 spike protein receptor binding domain and neutralizing antibody responses to COVID-19 vaccines longitudinally over 6 months in patients with cancer undergoing treatment or who received a stem cell transplant.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity. - 2 year(s) ago
e15613 Background: Fluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are commonly used chemotherapies for solid tumors, and essential for curative intent treatment of colorectal cancer. But sometimes, their use may be limited by cardiac toxicity limiting the possibility of cure in some patients. Cardiotoxicity could be asymptomatic (EKG changes) or manifested as chest pain,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@pashtoonkasi @doctorC369 @aparna1024 @OncoThor @AnwaarSaeed3 @CathyEngMD @benweinbergmd @gabe_a_brooks @DrR_DUNNE @mtmdphd Agree with everyone that bolus 5FU regimen is a good choice. Alternatively, we have implemented a cocktail of nitro paste, Norvasc and Ranolazine with good experience to prevent vasospasm from infusional 5FU or capecitabine (our ASCO abstract is here: https://t.co/zKKW7FRwat )
-
-
Mashup Score: 0
100 Background: CRC is a common cancer world-wide, accounting for ̃10% of cancer cases and mortality. Treatment options are limited, and survival is poor for pts with advanced disease, particularly those with mKRAS. After failure of 1L treatment for mCRC, regardless of KRAS mutation status, the ORR for FOLFIRI-bev is 5-13%, with PFS 4-6 mos, and OS 10-12 mos. Onvansertib is a highly selective,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Source: Let's Win! Pancreatic CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8
This systematic review and meta-analysis assesses the differences in rates of pathologic complete response, disease-free and overall survival, sphincter-preserving surgery, and ileostomy between patients with locally advanced rectal cancer receiving total neoadjuvant therapy vs standard…
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@MPishvaian @TumorBoardTues @manjuggm @DrBonillaOnc @aparna1024 @FlavioRochaMD @NirajGusani @isteaus @AnkitSarinMD @justinmaykel @salo75 @ChiaraCrem1 @SalemGIOncDoc @benweinbergmd @marshalj23 @GIcancerDoc @ShaalanBeg @WuGiOnc @KristenCiombor @AndreaCercek @TGeorgeMD @BenWestphalen @drgauravgangwni @NiuSanford Very practical point @manjuggm , our center also favor hypofractionation of radiation whenever feasible. This would be RAPIDO style TNT with short course RT and then chemo prior to rectal cancer surgery https://t.co/KiSNEHV8oM
-
@pashtoonkasi @MDAndersonNews @DrShubhamPant Kudos ! Mind blowing results ! KRAS vaccines seem to be promising in the early studies. On a similar note, our currently open KRAS vaccine trial for resected #pancreaticcancer provides an opportunity to treat and hopefully benefit more patients https://t.co/ESdpmvrV1V